GW joins a nationwide network of research centers in the Northeast ALS (NEALS) Consortium who are partnering with the Sean M HEALEY & AMG Center to conduct the first ALS platform trial. The platform trial is designed in a way that allows for testing multiple drugs simultaneously while reducing the amount of patients that receive placebo. The trail operates under a master protocol which outlines standard procedures that all drug regimens follow. Each drug that is being tested has its own regimen, which has a sub-protocol (under the master) that outlines procedures for that specific drug.
We are currently running Regimen E, which is investigating the efficacy of Trehalose. Enrollment is expected to close in February 2023. Follow this link for more information on Regimen E.
Regimen F, which is investigating ABBV-CLS-7262 is expected to open enrollment in late April/early May 2023. Follow this link for more information on this phase.
If you are interested or would like to learn more, please do not hesitate to reach out to our study coordinator, Grace Johnson. 202 741 2181. email@example.com